跳至主要内容
临床试验/NCT05909215
NCT05909215已完成4 期

Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

Sindh Institute of Urology and Transplantation1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2021年8月23日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
105
试验地点
1
主要终点
Hemodynamic Response

研究概览

简要总结

Two doses of Dexmedetomidine (0.5 µ/kg and 0.75 µ/kg) will be used to attenuate the stress response to laryngoscopy in American Society of Anesthesiology, physical class I patients which will be compared with the placebo-controlled group.

详细描述

A randomized, double-blind controlled trial will be conducted to determine the attenuation of stress response caused by laryngoscopy and tracheal intubation (LTI). After the Institutional Ethics Committee approval, (Sindh Institute of Urology and Transplantation, Pakistan), written informed consent will be obtained from 105 adult patients.

Randomization will be done using a computer-generated random number table. Patients will be divided into three groups. Group A "Placebo group", will receive 20 mL of normal saline (NS), Group B "dexmedetomidine 0.5", will receive dexmedetomidine 0.5 μ/kg, whereas, Group C "dexmedetomidine 0.75", will receive dexmedetomidine 0.75 μ/kg, all as a 20mL infusion through a syringe pump over 10 minutes followed by induction of general anesthesia.

No premedication will be given in the ward. Once the patients will arrive in the operating room, routine monitoring (electrocardiogram, pulse oximetry, non-invasive blood pressure) will be started. After recording the baseline vitals and Ramsay sedation score, the study drug or normal saline (according to randomization) will be given in a look-alike syringe over 10 minutes. The study drug will be prepared as a 20 mL solution in a 25 mL syringe. An independent co-investigator (anaesthesiologist) who will not be involved in administering general anesthesia or recording the study parameters will prepare the study drug(s) according to the body weight or NS using identical-looking syringes. Study drug infusion will be started once the patient is taken to the operating table. Vitals and sedation scores will be recorded at 0,1,3,5 and 10 minutes during infusion. Investigators will keep the atropine drawn in a syringe and ready to be given in case of heart rate goes below 40 beats/min. Ephedrine (5mg/ml) and adrenaline 10µ/ml will also be ready for use.

Once completing the infusion, general anesthesia will be administered using a standard protocol (Nalbuphine 0.15 mg/kg, Propofol 2.5 mg/kg, Atracurium 0.6 mg/kg after assessing easy bag-mask ventilation in all patients. After 3-minute bag-mask ventilation with Isoflurane at 1.5% in 100% oxygen, the trachea will be intubated by one of three senior anaesthesiologists involved in this study. The intubating duration will be kept below 15 seconds. Hemodynamic monitoring will be continued for another 10 minutes at 1, 3, 5 and 10 minutes after intubating the trachea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 18 to 55 years
  • ASA I or II patients undergoing surgery under general anaesthesia with endotracheal intubation.
  • Patients with Mallampati class I or II.

排除标准

  • ASA III & IV patients
  • Anticipated or unanticipated difficult intubations which requires more than 15 seconds or more than one attempt.
  • Patients with Mallampati class III, IV or with loose teeth.
  • Patients with inotropes infusion.
  • Patients with known allergy to any anaesthetic agents
  • Patients with a heart rate of 60 beats/min or less
  • Patients with known hypertension, incidental finding of hypertension while on operating table, diabetes, ischemic heart disease or peripheral vascular disease.
  • Pregnant and lactating mothers.

研究组 & 干预措施

Placebo

Placebo Comparator

20 mL of normal saline as an infusion through a syringe pump over 10 minutes followed by induction of general anesthesia.

干预措施: Normal saline (Drug)

Dexmedetomidine 0.5

Active Comparator

Dexmedetomidine 0.5 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.

干预措施: Normal saline (Drug)

Dexmedetomidine 0.5

Active Comparator

Dexmedetomidine 0.5 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.

干预措施: Dexmedetomidine 0.5 microgram/kg (Drug)

Dexmedetomidine 0.75

Active Comparator

Dexmedetomidine 0.75 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.

干预措施: Normal saline (Drug)

Dexmedetomidine 0.75

Active Comparator

Dexmedetomidine 0.75 μ/kg diluted in 20 mL normal saline through a syringe pump over 10 minutes followed by general anesthesia.

干预措施: Dexmedetomidine 0.75 microgram/kg (Drug)

结局指标

主要结局

Hemodynamic Response

时间窗: 0 to 10 minutes after endotracheal intubation

Mean change in the heart rate, systolic blood pressure, diastolic blood pressure, and mean arterial pressure will be assessed.

次要结局

  • Adverse events(0 to 30 minutes from the start of infusion to 10 minutes after endotracheal intubation))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Syed Muhammad Abbas

Associate Professor, Department of Anaesthesia

Sindh Institute of Urology and Transplantation

研究点 (1)

Loading locations...

相似试验